

Wnt/ β -Catenin

SKL2001

Wnt/ β -catenin pathway activator that disrupts the Axin/ β -catenin interaction leading to β -catenin stabilization.¹

Product No: 10-4379 5 mg 25 mg

LY2090314

Wnt/ β -catenin pathway activator that inhibits GSK-3 leading to β -catenin stabilization.²

Product No: 10-4854 5 mg 25 mg

ICG-001

ICG-001 inhibits TCF/ β -catenin mediated transcription by specifically blocking the β -catenin/CBP interaction.^{3,4}

Product No: 10-4378 5 mg 25 mg

Wnt-C59

Wnt-C59 is a potent inhibitor of the Wnt-acyltransferase Porcupine (PORCN).⁵

Product No: 10-4605 5 mg 25 mg

XAV-939

XAV-939 is a potent inhibitor of tankyrase 1 and 2. It antagonizes Wnt signaling via stimulation of β -catenin degradation and stabilization of actin.⁶

Product No: 10-1186 5 mg 25 mg

IWP-2

IWP-2 blocks Wnt-dependent signaling via inhibition of the Wnt acyltransferase Porcupine (PORCN).⁷

Product No: 10-1308 5 mg 25 mg

FH-535

FH-535 inhibits Wnt signaling by inhibiting the Tcf4/ β -catenin interaction.⁸

Product No: 10-1328 10 mg 50 mg

KY-02111

KY02111 inhibits Wnt signaling via a mechanism that appears to be distinct from other reported inhibitors.⁹

Product No: 10-1437 5 mg 25 mg

iCRT5

iCRT5 is a selective β -catenin-responsive transcription (CRT) inhibitor. Inhibition is via interfering with the β -catenin/Tcf4 interaction.¹⁰

Product No: 10-1371 5 mg 25 mg

IWR-1 endo

IWR-1 endo is a potent inhibitor of Wnt signaling.¹¹ Acts via inhibition of tankyrase.¹²

Product No: 10-5081 5 mg 25 mg

IM-12

IM-12 is a potent and selective inhibitor of GSK-3 β .¹³ It activates the Wnt/ β -Catenin signaling pathway.¹⁴

Product No: 10-5125 5 mg 25 mg

Nitazoxanide


Inhibits Wnt signaling independent of APC via targeting PAD2.¹⁵

Product No: 10-4633 10 mg 50 mg


Wnt/ β -Catenin Mini-Library

A collection of 12 inhibitors of various components of this pathway

Product No: 10-7305 DMSO solutions @ 10 mM



ICG-001



iCRT5

REFERENCES

1. Gwak *et al.* (2012) *Cell Res.* **22** 237
2. Atkinson *et al.* (2015) *PLoS One* **10** e0125028
3. Zhu *et al.* (2012) *J. Biol. Chem.* **287** 7026
4. Emami *et al.* (2004) *PNAS* **101** 12682
5. Profitt *et al.* (2013) *Cancer Res.* **73** 502
6. Huang *et al.* (2009) *Nature* **46** 614
7. Chen *et al.* (2009) *Nat. Chem. Biol.* **5** 100
8. Handeli *et al.* (2008) *Mol. Cancer Ther.* **7** 521
9. Minami *et al.* (2012) *Cell Rep.* **2** 1448
10. Gonsalves *et al.* (2011) *PNAS* **108** 5954
11. Chen *et al.* (2009) *Nature Chem. Biol.* **5** 100
12. Martins-Neves *et al.* (2018) *Cancer Lett.* **414** 1
13. Schmöle *et al.* (2010) *Bioorg. Med. Chem.* **18** 6785
14. Wang *et al.* (2019) *Cell Biol.* **97** 702
15. Qu *et al.* (2018) *Nat. Chem. Biol.* **14** 94